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Letters to the EditorImproving MELD for use in acute liver failureTo the Editor:
Bechmann et al. [1] presented an interesting modiﬁcation to the
Model for End-Stage Liver Disease (MELD) score using M-65, a
marker of hepatic necrosis, as a substitute for bilirubin in the
MELD equation which they subsequently applied to a series of
patients with acute liver failure (ALF). The statistical justiﬁcation
and reporting of the subsequent results is useful to discuss.
MELD is constructed (Eq. (1)) from serum creatinine, bilirubin,
and internationalized normalized ratio (INR), and is a highly suc-
cessful risk stratiﬁcation marker for death in patients with cirrho-
sis. While it is used for prognostication in ALF in the USA, there is
considerable doubt as to its applicability in this setting partly
because of the lack of utility of bilirubin as an early marker of dis-
ease severity in ALF. MELD was constructed [2] from a Cox-
proportional regression analysis of 231 patients with cirrhosis at
the time of transjugular intrahepatic portosystemic shunt (TIPSS),
where the quantitative predictors were logarithmically trans-
formed to reduce the effect of inﬂuential outliers. The coefﬁcients
seen in the MELD equation are the regression coefﬁcients derived
from the computation using these transformed predictors.
½MELD score ¼ 9:57 LnðCreatinineÞ þ 3:78 LnðBilirubinÞ
þ 11:2 LnðINRÞ þ 6:43 ð1Þ
Creatinine – mg/L, Bilirubin – mg/dL, INR – unitless.
Bechmann et al.’s implantation of M-65 into MELD in this ALF
cohort is concerning for a number of reasons. Their analysis is
based on outcome alone and not the length of survival and there-
fore uses logistic regression (via Receiver Operating Characteris-
tic (ROC) curves) not proportional hazards. In any multivariate
analysis, the independence of predictors must be assessed and
M-65, while having a clear univariate correlation with outcome,
was not tested against INR and creatinine in a logistic or propor-
tional hazards multivariate model. Furthermore, the effect of INR
and creatinine on survival in ALF is likely to be different from cir-
rhosis; in fact, de novo regression modeling may give different
regression coefﬁcients that lead to a more useful MELD improve-
ment rather than the assumption that the regression coefﬁcients
from patients with a different disease in a different country are
immediately transferable.
Improvements in modeling when assessed by ROC curve anal-
ysis can be assessed quantitatively as was lacking in the Bechman
et al. analysis. ROC curve comparisons via the Delong method [3]Journal of Hepatologyare non-parametric, well validated, and produce a p value for the
comparison. While sensitivity and speciﬁcity improvements were
discussed (again without quantitative comparators) and ROC
curves were produced, there was no head to head graphical or
quantitative ROC curve comparison between MELD and its mod-
iﬁcation or comparison among new multivariate models. These
would have strengthened the analysis.
Statistical models are not necessarily interchangeable
between diseases or populations, and repeat modeling is neces-
sary to provide evidence of validity of the model. Statistical
assessment of improvements of multivariate models is available
and should be reported to allow the quantitation of the signiﬁ-
cance of any improvement.
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E-mail address: m.mcphail@imperial.ac.ukReply to the Letter to the Editor ‘Improving MELD for use in acute
liver failure’This is a reply to the Letter to the Editor by Dr. McPhail:
The authors thank Dr. McPhail for initiating this valuable dis-
cussion on our manuscript. We agree with Dr. McPhail that the
MELD score was initially developed to stratify the risk of death2in a cohort of patients with end-stage chronic liver disease to
predict death after a TIPS procedure, as we pointed out in the
introduction of the original manuscript [1,2]. We thus agree with
Dr. McPhail that the MELD score was neither primarily designed011 vol. 54 j 1320–1326
